Interleukin-7/b7.1-encoding Adenoviruses Induce Rejection of Updated Version Cited Articles Citing Articles E-mail Alerts Interleukin-7/b7.1-encoding Adenoviruses Induce Rejection of Transplanted but Not Nontransplanted Tumors

Most cancer vaccine trials are based on efficacy studies against transplanted mouse tumors that poorly reflect the clinical situation. We constructed adenoviruses expressing interleukin-7 and B7.1 and tested their therapeutic efficacy after transfer into established transplanted and nontransplanted 3-methylcholanthrene-induced tumors. The adenoviruses efficiently induced rejection of transplanted tumors, leaving behind systemic immunity. Against nontransplanted tumors of similar size, there were almost no therapeutic effects. This result was not due to the site of tumor development, tumor type, general immune suppression, or differences in transduction efficacy. Adenoviral expression of beta-galactosidase as a surrogate antigen in nontransplanted tumors induced cytotoxic T cells that were unable to quantitatively reach the tumor site. Based on rigorous mouse models and an effective in situ immunization procedure, it is suggested that cancer vaccines can be effective, if at all, against "minimal residual disease"; additional experimental procedures must be found against established nontransplanted tumors.

[1]  R. Bright.  Peptide-Based Cancer Vaccines , 2002, Leukemia.

[2]  M. Kanda,et al.  Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. , 1999, Cancer research.

[3]  Ferry Ossendorp,et al.  CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.

[4]  M. Hanna,et al.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.

[5]  D. Hanahan,et al.  Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. , 1998, Cancer research.

[6]  J. Alferink,et al.  Failure to induce organ‐specific autoimmunity by breaking of tolerance: importance of the microenvironment , 1998, European journal of immunology.

[7]  R. Offringa,et al.  Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. , 1998, Cancer research.

[8]  James M. Wilson,et al.  Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers , 1998, Journal of Virology.

[9]  F. Graham,et al.  A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. , 1998, Journal of immunology.

[10]  F. Graham,et al.  Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[12]  J. Bluestone,et al.  Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.

[13]  G. Klein.  Rejection antigens in chemically induced tumors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Coulie,et al.  Tumor antigens recognized by T cells. , 1997, Immunology today.

[15]  B. Dörken,et al.  Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. , 1997, Journal of immunology.

[16]  K. Hellström,et al.  B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. , 1997, Journal of immunology.

[17]  J. Wilson,et al.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. , 1996, Human molecular genetics.

[18]  N. Restifo.  The new vaccines: building viruses that elicit antitumor immunity. , 1996, Current opinion in immunology.

[19]  Steinman Rm.  Dendritic cells and immune-based therapies. , 1996 .

[20]  B. Baum,et al.  Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. , 1996, Human gene therapy.

[21]  D. Pardoll,et al.  Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? , 1996, The Journal of experimental medicine.

[22]  Lieping Chen,et al.  B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes , 1996, The Journal of experimental medicine.

[23]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[24]  Ronald G. Crystal,et al.  Transfer of Genes to Humans: Early Lessons and Obstacles to Success , 1995, Science.

[25]  B. Dörken,et al.  Tumor cells cotransfected with interleukin‐7 and B7.1 genes induce CD25 and CD28 on tumor‐infiltrating T lymphocytes and are strong vaccines , 1995, European journal of immunology.

[26]  M. Battegay,et al.  Fibroblasts as efficient antigen-presenting cells in lymphoid organs. , 1995, Science.

[27]  F. Graham,et al.  Methods for construction of adenovirus vectors , 1995, Molecular biotechnology.

[28]  M. Kay,et al.  Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. , 1995, Gene therapy.

[29]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Leinwand,et al.  The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. , 1994, Gene therapy.

[31]  F. Graham,et al.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[33]  G. Forni,et al.  Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. , 1993, Cancer research.

[34]  M. Bevan,et al.  Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. , 1993, Journal of immunology.

[35]  T. Blankenstein,et al.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Blankenstein,et al.  Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. , 1993, Cancer research.

[37]  M. Dewhirst,et al.  Diminished leukocyte-endothelium interaction in tumor microvessels. , 1992, Cancer research.

[38]  H. Schreiber,et al.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells , 1992, The Journal of experimental medicine.

[39]  T. Blankenstein,et al.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection , 1991, The Journal of experimental medicine.

[40]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[41]  H. Volk,et al.  Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer , 1991, The Journal of experimental medicine.

[42]  S. Dower,et al.  Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7- dependent cell line , 1990, The Journal of experimental medicine.

[43]  R K Jain,et al.  Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.

[44]  F. Graham,et al.  A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. , 1988, Virology.

[45]  E. A. Havell,et al.  The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma , 1988, The Journal of experimental medicine.

[46]  W. Fiers,et al.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity , 1988, The Journal of experimental medicine.

[47]  F. Schabel,et al.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. , 1975, Cancer research.

[48]  G. Klein,et al.  Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non‐immunized semi‐syngeneic mice against a mouse lymphoma line , 1975, International journal of cancer.

[49]  Basombrío Ma,et al.  Studies on the basis for diversity and time of appearance of antigens in chemically induced tumors. , 1972 .

[50]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[51]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[52]  Foley Ej.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953 .

[53]  L. Gross.  Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line , 1943 .

[54]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[55]  B. Dörken,et al.  Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells. , 1997, Experimental hematology.

[56]  T. Blankenstein,et al.  Genetic approaches to cancer immunotherapy. , 1996, Reviews of physiology, biochemistry and pharmacology.

[57]  R. Steinman.  Dendritic cells and immune-based therapies. , 1996, Experimental hematology.

[58]  R. Prehn,et al.  Studies on the basis for diversity and time of appearance of antigens in chemically induced tumors. , 1972, National Cancer Institute monograph.

[59]  E. J. Foley.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953, Cancer research.